Survodutide
PMID 42253238 reports mean weight loss at week 76 of 12.2% (95% CI 10.8–13.6) and 13.0% (95% CI 11.6–14.4) in two Survodutide groups (checked: 2026-08-25). The placebo group lost a mean 5.4% (95% CI 4.0–6.9). The trial included 725 adults with obesity and no diabetes. Boehringer Ingelheim funded the trial.
What is Survodutide?
The WHO Recommended INN List 90 names survodutide (checked: 2026-08-25). The USAN record gives the development code BI 456906. It gives UNII 2ALA66NS64. It gives CAS 2805997-46-8.
The phase 3 paper says the drug is still being studied. It acts at both the glucagon and GLP-1 receptors (PMID 42253238; checked: 2026-08-25).
The primary trials on this page compare Survodutide with placebo. They provide no head-to-head result against Retatrutide or Tirzepatide.
What did the phase 3 obesity trial report?
PMID 42253238 was a 76-week phase 3 trial (checked: 2026-08-25). Boehringer Ingelheim funded it. The trial split 725 adults at random into three groups. They had obesity and no diabetes. Its main analysis kept early stops and barred weight-loss drugs in the result.
| Group in PMID 42253238 | People | Mean weight loss at week 76 | 95% interval | Lost at least 5% | Funder |
|---|---|---|---|---|---|
| Survodutide, adjusted up to 3.6 mg | 241 | 12.2% | 10.8–13.6% | 72.6% | Boehringer Ingelheim |
| Survodutide, adjusted up to 6.0 mg | 242 | 13.0% | 11.6–14.4% | 71.9% | Boehringer Ingelheim |
| Placebo | 242 | 5.4% | 4.0–6.9% | 46.3% | Boehringer Ingelheim |
All comparisons with placebo had a p-value below 0.001 in PMID 42253238. These are trial amounts, not a Survodutide dosage for use outside the study.
What adverse events did the phase 3 trial record?
Gut symptoms occurred in 80.9% of the 3.6 mg group in PMID 42253238. They occurred in 89.7% of the 6.0 mg group. They occurred in 47.9% of the placebo group. The paper says they were usually mild or moderate. It reports no deaths.
What did the MASH trial report?
PMID 38847460 was a 48-week phase 2 trial (checked: 2026-08-25). Boehringer Ingelheim funded it. A total of 293 adults took at least one dose. A liver biopsy had shown MASH and fibrosis from stage F1 through F3.
| Finding in PMID 38847460 | 2.4 mg | 4.8 mg | 6.0 mg | Placebo | Funder |
|---|---|---|---|---|---|
| MASH improved without fibrosis worsening | 47% | 62% | 43% | 14% | Boehringer Ingelheim |
| Liver fat fell by at least 30% | 63% | 67% | 57% | 14% | Boehringer Ingelheim |
| Fibrosis improved by at least one stage | 34% | 36% | 34% | 22% | Boehringer Ingelheim |
The best-fit dose curve had p < 0.001 in PMID 38847460. The paper gives no intervals for these shares. It does not give a sample count for each arm.
What adverse events did the MASH trial record?
Nausea occurred in 66% of the drug groups and 23% of the placebo group in PMID 38847460. Diarrhoea occurred in 49% and 23%. Vomiting occurred in 41% and 4%. Serious events occurred in 8% and 7%.
How strong is the evidence and what is the status?
Evidence tier: B (checked: 2026-08-25). Trials in people exist. One published result is phase 3. A trial phase does not prove approval.
EU status: investigational (checked: 2026-08-25). NCT06066515 is a finished phase 3 trial. Boehringer Ingelheim is the sponsor.
The EMA record P/0259/2024 is a study plan for children with obesity (checked: 2026-08-25). It is a drug-development record. It is not a marketing approval.
What did grey-market vial testing show?
A 2026 preprint analysed 6,285 lab reports for 14 compounds. Survodutide was in that set (checked: 2026-08-25).
The text read gives no report count for this drug. It gives no median amount for it. It gives no identity-failure rate or purity value for it. It gives no endotoxin or sterility result for it.
→ What vial testing can and cannot show
When was Survodutide first observed outside research?
No sound first month is known (checked: 2026-08-25). The vial-study window ended on 3 April 2026. The paper gives no first date for this drug. The register therefore keeps first_observed: null.
The collection-window endpoint is not the first month of circulation.
What do users report?
The checked forum list contains no Survodutide thread (checked: 2026-08-25). This page therefore has no forum quote or group claim.